Detailed description of Pimitespib’s launch time and drug purchasing channels in China

Pimitespib (Pimitespib) has not yet been officially approved for drug marketing in mainland China, so it cannot be purchased through formal channels in domestic hospitals and pharmacies. Due to the lack of domestic registration approval, the clinical use of this drug in China still falls under the category of "overseas import". Patients who wish to use it must obtain it through cross-border drug purchase, international medical services, or self-paid import.

In overseas markets, the currently existing pimotibi is mainly the "Japanese version of the original drug" version. This version has passed relevant approvals in Japan and is used to treat some indications such as gastric cancer. Because it is an original drug, the price is relatively high, equivalent to about more than 10,000 yuan per box. There are currently no generic versions available overseas, so the Japanese version of the original drug is currently the most common and reliable choice for patients.

In terms of drug purchase channels, patients can consider the following methods: First, purchase through international mail through regular Japanese pharmacies or authorized pharmaceutical platforms, but it is necessary to ensure that the channel is legal and has formal qualifications, and pay attention to customs clearance and drug storage issues in international transportation; second, assist in importing through international medical service agencies or hospital overseas pharmacies, relying on the channel coordination and compliance procedures of medical institutions; third, through international pharmaceutical purchase platforms, but such channels have higher risks, and it is necessary to carefully choose suppliers with good reputation and quality assurance to avoid counterfeit drugs or substandard varieties.

Generally speaking, pimetibib has not yet been launched in China, and patients cannot purchase it through domestic formal channels. Only Japanese original drugs are available for purchase overseas, which are expensive and have complicated import procedures. In the future, if it is approved for listing in China and included in medical insurance or regular channels, its accessibility will be greatly improved. When considering using it, patients should give priority to consulting an oncologist and purchase drugs through formal channels and legal procedures to ensure drug safety and efficacy.

Reference materials:https://www.drugs.com/